Blog

A new UC San Diego-led study titled “GLP-1 Shows Promise for Patients with Advanced Fatty Liver Disease” provides encouraging evidence that GLP-1 receptor agonists may benefit patients with advanced metabolic… Read more: GLP-1 Effect in Liver

Give this article a read: “Chronic Liver Disease: How PCPs Can Improve Early Detection.” This HCPLive interview with Stevan Gonzalez, MD, MS (Director of Liver Transplantation at Baylor Scott &… Read more: Liver Disease: Screenalot

Here’s a summary of the paper titled: Machine Learning–Assisted Detection of Advanced Liver Fibrosis in Primary Care (2025) One-sentence summary The study found that an AI/machine learning approach applied to… Read more: Find HCC Earlier

The LinkedIn article titled “Trinity Health Aims to Improve Liver Cancer Screening Rates Through Physician, Patient Education Intervention” highlights a small but potentially high-impact initiative by Trinity Health West Michigan… Read more: Trinity Health Innovation in HCC

This new Clinical Gastroenterology and Hepatology (CGH) study is one of the strongest observational studies to date examining coffee and liver health because it combines long-term clinical outcomes with liver… Read more: Coffee and Liver Health

The PharmaVoice article titled “3 late-stage MASH drugs that could rival Rezdiffra” highlights the next wave of MASH therapies expected to compete with Madrigal’s Rezdiffra (resmetirom), emphasizing that the future… Read more: New MASH Drugs

Here are the key takeaways from the HCPLive article, “Lifestyle, Pharmacologic Therapies, and EXCEL Trial Data Reshape MASLD Treatment Framework,” by Dr. Zobair Younossi (published June 23, 2026). 1. MASLD… Read more: MASLD Treatment: New Era

It’s straightforward.

This LinkedIn post highlights a major milestone by the Beth Israel Deaconess Medical Center (BIDMC) Transplant Institute. “The robotic approach brought a new dimension to an already complex operation led… Read more: Robotic Liver Transplant at Beth Israel

Summary: Microplastics May Worsen Fatty Liver Disease, New Study Suggests Researchers at the University of Oklahoma have found that microplastics may significantly worsen fatty liver disease, especially when combined with… Read more: Microplastics and Liver Disease

Summary: “Why Are Liver Cancer Rates Rising in the U.S.?” (AARP) The video explains that liver cancer rates in the United States have tripled over the past 40 years, with… Read more: Liver Cancer Rising: Why?

It’s very very low awareness today, Hepatology aka Liver Disease. Thus we started a free website aimed at the 4 Ps — Patients / Providers / Payers / Pharmas, called… Read more: Liver Disease Awareness

LiverRight Announces the Liververse™: Offering Referring Primary Care, GI and Endocrinology Practices Same-Week Telemedicine Appointment Access for Their Liver Patients For Providers with Liver Elastography (TE/SWE), an Additional Option of… Read more: Hello, Liververse

Per the article from FirstWorld Pharma titled “Nudge increases prescriptions of medication for drinking“, published June 9, 2026– A “nudging” strategy in the emergency department (ED) may be a path for prescribing… Read more: Nudging in AUD

Summary: Quality of Life Remains Stable in Autoimmune Liver Disease (EMJ Hepatology, June 2026) The article reports on a longitudinal study of 252 patients with autoimmune liver diseases (AILD)—including autoimmune… Read more: Autoimmune Liver Disease (AILD)

The article titled “New study reveals turbocharged GLP-1 drug helps shed body weight and fat in the liver” delineates a VCU Health report on survodutide, a next-generation obesity/liver disease drug… Read more: GLP-1s and Fat In the Liver

THE FEHV: The  Foundation for the Study of Viral Hepatitis is a  leading international non-profit organization in the field of hepatology , with  top specialists  in  liver diseases  and molecular biology. At our clinic in Madrid, we treat… Read more: Fatty Liver and Hepatitis B

EASL has come and gone for the year and this article is a stellar summary: From EASL 2026: “What Hepatology Still Needs to Solve.” The AJMC article highlights a panel… Read more: EASL 2026 Summary

The article, “A therapeutic turning point in metabolic liver disease” (npj Gut and Liver, June 2026), is an editorial that argues the field of metabolic liver disease has entered a… Read more: Turning Point in Liver Disease

We will miss Tony Villiotti’s peerless innovation in moving liver disease in America from very low awareness among patients, payers and providers, to its current state of surging enthusiasm, energy… Read more: Pillar of Liver Disease Awareness: Tony Villiotti

The 05/26/2026 article “The importance of reading your medical records when living with MASH” from Liver Disease News powered by Bionews highlights how reading your own medical records can be… Read more: MASH and your Medical Records

Roche announced a new “Liver Disease Panel,” which it says is the first certified suite of digital algorithms designed to help clinicians detect and manage chronic liver disease (CLD) earlier… Read more: New Liver Disease Panel from Roche

This May 26, 2026 article cleverly titled “From Margin to Mainstream: Why Liver Health Should Sit at the Centre of the Global NCD Response” by Jeffrey Lazarus in Health Policy… Read more: Liver Disease Mainstream

It’s a complex organ– 1. Your liver can regenerate itselfIt’s the only internal organ that can regrow lost tissue. Even if up to about 70% is removed, it can regenerate… Read more: Meet the Human Liver

Big Gilead news: “FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)“. Gilead announced that the FDA has granted… Read more: HEPCLUDEX Approval

The article titled “Hepatitis C Treatment Could Save Billions” explains that expanding access to HCV treatment—especially among Medicaid patients—could generate major long-term healthcare savings while dramatically improving patient outcomes. Key… Read more: HCV Treatment Savings

This May 16, 2026 Cureus review titled “Metabolic Dysfunction-Associated Steatotic Liver Disease: Current Diagnostic Pathways, Noninvasive Fibrosis Assessment, and Therapeutic Strategies” is essentially a “state of the field” overview of… Read more: State of MASLD